Likewise, HR−HER2-positive breast cancer showed more differentially mutated genes (ERBB2, PRKDC, PTEN and NEB) than HR−HER2-zero breast cancer (only SLX4) compared to HR−HER2-low breast cancer (3 vs 1) (Fig. 3B and C). This evidence concerns the gene PTEN and breast carcinoma.